Financial Review: Akorn (AKRX) and Its Peers
Akorn (NASDAQ: AKRX) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Akorn to related companies based on the strength of its analyst recommendations, risk, institutional ownership, valuation, earnings, dividends and profitability.
This table compares Akorn and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Akorn has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Akorn’s rivals have a beta of 33.82, indicating that their average share price is 3,282% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Akorn and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Akorn presently has a consensus price target of $29.13, suggesting a potential downside of 12.14%. As a group, “Pharmaceuticals” companies have a potential upside of 20.42%. Given Akorn’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Akorn has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
69.4% of Akorn shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 28.2% of Akorn shares are owned by insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Akorn and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Akorn||$1.12 billion||$184.24 million||33.48|
|Akorn Competitors||$8.39 billion||$1.12 billion||134.42|
Akorn’s rivals have higher revenue and earnings than Akorn. Akorn is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Akorn rivals beat Akorn on 8 of the 13 factors compared.
Akorn Company Profile
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.